American Bio Medica Corporation (ABMC) filed on Wed, August 14 8-K Form

American Bio Medica Corporation (OTCMKTS:ABMC) Logo

American Bio Medica Corporation (ABMC) files 8-K in a filing on August 14, 2019.

ITEM 2.02           RESULTS OF OPERATIONS AND FINANCIAL CONDITION   On August 14, 2019, American Bio Medica Corporation (the “Company”) announced financial results for the three and six months ended June 30, 2019. A copy of the press release announcing the Company’s results (the “Press Release”) is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 2.02. The Press Release is available on the Company’s website. The information provided in Item 2.02 of this report, including Exhibit 99.1, shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.   ITEM 8.01             OTHER EVENTS   As disclosed in the Company’s prior periodic reports filed with the Commission, the Company previously commenced a lawsuit against Todd Bailey (“Bailey”) and Premier Biotech, Inc. Bailey asserted counterclaims against the Company. After further investigation, the parties have decided to dismiss all claims made against each other.   To this end, the parties entered into a Settlement Agreement and Release (“Settlement Agreement”) in which the parties elected to resolve the litigation. As a result of the execution of the Settlement Agreement, both parties have agreed to dismiss all claims made against each other.

On August 14, 2019, American Bio Medica Corporation (the “Company”) announced financial results for the three and six months ended June 30, 2019. A copy of the press release announcing the Company’s results (the “Press Release”) is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 2.02. The Press Release is available on the Company’s website. The information provided in Item 2.02 of this report, including Exhibit 99.1, shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

As disclosed in the Company’s prior periodic reports filed with the Commission, the Company previously commenced a lawsuit against Todd Bailey (“Bailey”) and Premier Biotech, Inc. Bailey asserted counterclaims against the Company. After further investigation, the parties have decided to dismiss all claims made against each other.

To this end, the parties entered into a Settlement Agreement and Release (“Settlement Agreement”) in which the parties elected to resolve the litigation. As a result of the execution of the Settlement Agreement, both parties have agreed to dismiss all claims made against each other.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

It closed at $0.07 lastly. It is down 0.00% since August 14, 2018 and is . It has by 0.00% the S&P500.

American Bio Medica Corporation develops, makes, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. The company has market cap of $2.28 million. The Company’s drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; Rapid ONE product line that consists of single drug tests, each of which tests for the presence or absence of a single drug; Rapid Reader, a portable device that interprets the results of drug screen; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 14 drugs; and Rapid TOX Cup II which consists of a smaller cup with smaller test strip, as well as private labeled versions of Rapid TOX. It currently has negative earnings. The firm also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.